Enpatoran Demonstrates Sustained Benefits in Lupus Over 48 Weeks, suggests study medicaldialogues.in To view or add a comment, sign in In a mouse model of obesity-induced metabolic inflammation that accelerates leukemogenesis dual therapy with an anti-IL-17A antibody and a GLP-1R agonist beinaglutide reduced M2-like TAMs, restoring Ciita-dependent antigen presentation, Tyk2-mediated IFN signaling, reactivated T-cell responses, and reduced leukemic burden
Some of the most common side effects include: Nausea, vomiting, diarrhea, and constipation are frequently reported
Read the teams full article here.
Further, many employers (as high as 59% of employers with at least 5,000 workers) that offered such coverage said that use of GLP-1 medications was higher than expected, and 66% of the largest employers said that covering such drugs for weight loss had a significant impact on their health plans prescription drug spending